Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/11350
When should we order a next generation sequencing test in a patient with cancer?
Colomer, Ramon | Mondejar, Rebeca | Romero-Laorden, Nuria CNIO | Alfranca, Arantzazu ISCIII | Sanchez-Madrid, Francisco CNIC | Quintela Fandino, Miguel Angel CNIO | colomer
EClinicalMedicine. 2020 ;25:100487.
Technical advances in genome sequencing and the implementation of next-generation sequencing (NGS) in clinical oncology have paved the way for individualizing cancer patient therapy based on molecular profiles. When and how to use NGS testing in the clinic is at present an unsolved issue, although new research results provide evidence favoring this approach in some types of advanced cancer. Clinical research is evolving rapidly, from basket and umbrella trials to adaptative design precision oncology clinical studies, and genomic and molecular data often displace the classical clinical validation procedures of biomarkers. In this context, physicians must be aware of the clinical evidence behind these new biomarkers and NGS tests available, in order to use them in the right moment, and with a critical point of view. This review will present the status of currently available targeted drugs that can be effective based on actionable molecular alterations, and the NGS tests that are currently available, offering a practical guide for the application of Clinical Precision Oncology in the real world routine practice.
PRECISION ONCOLOGY | PERSONALISED MEDICINE | NEXT GENERATION SEQUENCING | cANCER GENOMICS | CANCER THERAPY | TARGETED THERAPY
Files in this item
- Artículo principal